http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102887834-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4827ad278df426e5e569d83ec2c51d6e
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C249-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C251-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-15
filingDate 2011-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5c3e37b733fa64a216ac281e0406657
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e15f36f9901fc9a94145ee72ff6deb7a
publicationDate 2013-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102887834-A
titleOfInvention 1-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-1-acetone oxime and its application
abstract The invention discloses a 1-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-1-acetone oxime and its application. The invention is based on the structure-activity of FTY720 According to the analysis, 1-[4-[3-amino-4-hydroxyl-3-(hydroxymethyl)butyl]phenyl]-1-acetone oxime was successfully synthesized. It can be used to prepare drugs and/or immunosuppressant drugs for the treatment of lung injury and/or pulmonary fibrosis, and provide a more effective and safer alternative drug for the treatment of lung injury and pulmonary fibrosis, which has the formula (1 ) or a salt thereof:
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113480455-A
priorityDate 2011-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465265244
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163637267

Total number of triples: 17.